MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 1.6% – Here’s Why

MiNK Therapeutics, Inc. (NASDAQ:INKT) shot up 1.6% on Tuesday . The stock traded as high as $11.46 and last traded at $11.19. 4,134 shares were traded during trading, a decline of 61% from the average session volume of 10,684 shares. The stock had previously closed at $11.01.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INKT. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Trading Up 1.6%

The firm has a 50-day moving average of $11.91 and a two-hundred day moving average of $13.28. The firm has a market cap of $52.48 million, a price-to-earnings ratio of -3.69 and a beta of 0.34.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.21. As a group, equities analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 EPS for the current year.

Institutional Trading of MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors and hedge funds.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.